Combination of Nanoxel and Herzuma in Salivary Duct Carcinoma

Salivary Duct Carcinoma Clinical Trial

Official title:
Combination of Nanoxel and Herzuma as First-line Chemotherapy in Patients With Metastatic Salivary Duct Carcinoma : Open Label Single Arm Multicenter Phase II Study

Status Active, not recruiting

Clinical Trial Summary

1. Study outline This is a multicenter, single-arm, phase II trial to evaluate the efficacy and safety of nanoxel plus herzuma combination chemotherapy in patients with metastatic salivary ductal cancer. Approximately 41 patients will be enrolled. Treatment will be continued until disease progression or unacceptable toxicities. Response evaluation will be performed every 2 cycles. 2. Dosing & Treatment schedule D1 Nanoxel 75 mg/m2 + D5W 100mL MIV over 1hr D1 Herzuma 8mg/kg (loading dose) + N/S 250mL miv over 90mins 6mg/kg (maintenance) + N/S 250mL MIV over 30mins (since 2 cycle) repeated every 3 weeks (In case of discontinuation of nanoxel without progression, single agent herzuma can be administered until progression)

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03614364
Study type	Interventional
Source	Samsung Medical Center
Contact
Status	Active, not recruiting
Phase	Phase 2
Start date	September 20, 2018
Completion date	August 2023

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05513365` - Phase II Dutasteride in Combination With CAB vs CAB in SDC	Phase 2
Completed	`NCT03319641` - PSMA-PET Imaging for Advanced ACC/SDC	N/A
Completed	`NCT04291300` - Lutetium-177-PSMA Radioligand Therapy in Advanced Salivary Gland Cancer Patients	Phase 2
Recruiting	`NCT04214353` - PSMA-PET Imaging Before and After ADT in Advanced SDC Patients	N/A
Active, not recruiting	`NCT04249947` - P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC)	Phase 1